CLAIMS

1. Use of a thaizolide agent in the preparation of a medicament for treating an illness caused by a virus belonging to the *Coronaviridae* family, wherein the medicament is to be administered to a subject in need thereof to produce an effective concentration of tizoxanide in a plasma of the subject, wherein the subject displays one or more symptoms of the illness.

2. The use of claim 1, wherein the one or more symptoms further comprise one or more respiratory symptom selected from the group consisting of cough, sore throat, and nasal congestion.

3. The use of claim 1 or 2, wherein the one or more symptoms further comprise one or more constitutional symptoms selected from the group consisting of fatigue, headache, myalgia, and feverishness.

4. The use of any one of claims 1-3, wherein the oral temperature is no less than 37.3ºC.

5. The use of claim 4, wherein the oral temperature is no less than 37.7ºC.

6. The use of any one of the preceding claims, wherein the virus belonging to the *Coronaviridae* family is the sole cause of the illness.

7. The use of any one of claims 1-6, wherein the virus belongs to the *Alphacoronavirus* genus.

8. The method of any one of claims 1-6, wherein the virus belongs to the *Betacoronavirus* genus.

9. The use of any one of claims 1-6, wherein the virus is selected from the group consisting of NL63 coronavirus, HKU1 coronavirus, 229E coronavirus, and OC43 coronavirus.

10. Use of a thaizolide agent in the preparation of a medicament for preventing a viral respiratory illness, wherein the medicament comprising an effective amount of the thiazolide agent is to be administered to a subject who does not display a symptom of the viral respiratory illness, to produce an effective concentration of tizoxanide in a plasma of the

subject.

11. The use of claim 10, wherein the viral respiratory illness is caused by a virus belonging to the *Coronaviridae* family.

12. Use of a thaizolide agent in the preparation of a medicament for treating a mild or moderate illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), wherein the medicament is to be administered to a subject in need to produce an effective concentration of tizoxanide in a plasma of the subject.

13. The use of claim 12, wherein the medicament comprising the thiazolide agent reduces progression of the subject from the mild or moderate illness to a severe illness.

14. The use of claim 12 or 13, wherein the medicament comprising the thiazolide agent reduces a symptom duration of the mild or moderate illness.

15. The use of any one of claims 12-14, wherein the medicament comprising the thiazolide agent is to be first administered within 72 hours of a symptom onset of the mild or moderate illness in the subject.

16. The use of claim 15, wherein the medicament comprising the thiazolide agent is to be first administeredless than 36 hours of the symptom onset of the mild or moderate illness in the subject.

17. The use of any one of the preceding claims, wherein the thiazolide agent comprises tizoxanide or a pharmaceutically acceptable salt thereof.

18. The use of any one of claims 1-16, wherein the thiazolide agent comprises a prodrug of tizoxanide.

19. The use of any one of claims 1-16, wherein the thiazolide agent comprises RM-5061.

20. The use of any one of claims 1-16, wherein the thiazolide agent comprises nitazoxanide.

21. The use of claim 20, wherein the medicament comprises a pharmaceutical

composition comprising nitazoxanide.

22. The use of claim 21, wherein the pharmaceutical composition is an extended release pharmaceutical composition.

23. The use of claim 21 or 22, wherein the pharmaceutical composition is administered orally.

24. The use of any one of claims 21-23, wherein a daily dose of nitazoxanide to be administered is about 1200 mg.

25. The use of claim 24, wherein the daily dose is to be administered in two administering events per day.

26. The use of any one of claims 24-25, wherein the pharmaceutical composition comprising nitazoxanide is to be administered for at least 5 days.

27. The use of any one of claims 1-9 and 12-26, wherein the medicament reduces a time from a first administering event for the thiazolide agent till the subject returns to usual health.

28. The use of any one of claims 1-9 and 12-26, wherein the medicament reduces a time from a first administering event for the thiazolide agent till the subject is able to perform normal activities.